The use of the terms 'lifestyle medicines' or 'lifestyle drugs'

Pharmacy World and Science

Volumn 26, Issue 4, 2004, Pages 193-196

  Møldrup, Claus ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Discrimination; Drugs; Lifestyle medicines; Terminology

Indexed keywords

AMFEBUTAMONE; APOMORPHINE; CAFFEINE; COCAINE; DRUG; FINASTERIDE; FISH OIL; FLUOXETINE; MINOXIDIL; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PROSTAGLANDIN E1; RETINOIC ACID; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SIBUTRAMINE; SILDENAFIL; TAZAROTENE; TETRAHYDROLIPSTATIN;

DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW;

DENMARK; DOCUMENTATION; DRUG UTILIZATION; EXPERT TESTIMONY; INFORMATION STORAGE AND RETRIEVAL; LIFE STYLE; TERMINOLOGY; VOCABULARY, CONTROLLED;

EID: 4043166364     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:PHAR.0000035917.09650.1c     Document Type: Review

References (35)

1. Nutton V. The rise of medicine. In: Porter R, editor. Cambridge Illustrated medicine. Cambridge, UK: Cambridge University Press, 1996; 52-82.
2. Gross P, Hitzler R, Horner A. Zwei Kulturen? Diagnostische und terapeutische Kompetenz im Wandel. [Two cultures: diagnostic and therapeutic competence in a state of change.] Öster Z Soziol Sonderheft Medizinsoziol 1985.
3. Brock D. The use of drugs for pleasure-some philosophical issues. In: Murray T, Gaylin W, Macklin R, editors. Feeling good and doing better: ethics and nontherapeutic drug use. Clifton, New Jersey: Humana Press, 1984; 83-106.
4. Shapiro MH. The technology of perfection: performance enhancement and the control of attributes. South California Law Rev 1991; 65: 11-13.
5. Audran M, Gareau S, Matecki F, Durand F, Chenard C, Sicart M et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exercise 1999; 31: 639-45.
6. Waddington I. Sport, health and drugs: a critical sociological perspective. London: Spon Press 2000.
7. Donohoe T, Johnson N. Foul play: drug abuse in sports. New York: Basil Blackwell, 1986.
8. Kuhn C, Scott S, Wilke W. The straight facts about the most used and abused drugs from alcohol to ecstasy. New York: Norton, 1998.
9. Sherlock K, Conner M. Patterns of ecstasy use amongst club-goers on the UK 'dance scene'. Int J Drug Policy 1999; 10: 117-29.
10. Møldrup C. Den medicinerede normalitet. [Medical normality.] Gyldendal: Copenhagen 1999 [in Danish].
11. Møldrup C. Fremtidens medicinsk optimeret krop. In: Balling G. editor. Homo Sapiens 2.0. Copenhagen: GAD, 2002; 105-21 [in Danish].
12. Møldrup C, Morgall JM. Risk Society - reconsidered in a drug context. Health, Risk Society 2001; 3: 59-74.
13. Knudsen P, Hansen EH, Traulsen JM. Perceptions of younger woman using SSRI antidepressants - a reclassification of stigma. Int J Pharm Pract 2002; 10: 243-52.
14. Slomka J. Playing with Propranolol. Hastings Center Report 1992; 22: 13-7.
15. Van Zanten MA, De Smidt JH, Kok-Van-Esterik JAE, Broekmans AW. Lifestyle drugs do not exists. A matter of use. Pharm Weekly 2001; 136: 1274-76.
16. 6 Young SN. Lifestyle drugs, mood, behaviour and cognition. J Psych Neurosci 2003; 28: 87-9.
17. Gilbert D. Lifestyle drugs; who will pay? Scrip report. London: PJB Publications 1999.
18. Walley T. Lifestyle medicines and the elderly. Drugs Aging 2002; 19: 163-8.
19. Concise Oxford Dictionary. 10th ed. Oxford: Oxford University Press, 1999.
20. Klein R, Sturm H. Viagra: a success story for rationing? Health Affaires 2002: 21; 177-87.
21. Lifestyle drugs: potion for growth. Internet Communication, 2003. http://www.Equitymaster.com (10 Aug. 2003).
22. Reuters Business Insight. Lifestyle Drugs Outlook to 2007: challenges and opportunities in a high-profile growth market New Strategic Management Report. London: Reuters, 2002.
23. Overman S. Warning: Viagra may cause headaches for health insurers. HR Magazine 1998; Sep: 104-9.
24. Sevon M, Murany D. Quality of life drugs: framing the issue. Internet Communication 2001. http://www.amcp.org/data/ jmcp/vol15/num3/spotlight.html (16 June 2004).
25. Laurance J. Should self-esteem be available at NHS? Independent 2001; 9.
26. Go on, it's good for you. Editorial, The Economist, 6 Aug. 1998; 3.
27. Frankel S, Ebrahim S, Davey Smith G. The limits to demand for health care. BMJ 2000; 321: 40-5.
28. Gilbert D, Walley T, New B. Lifestyle medicines. BMJ 2000; 321: 1341-4.
29. Wick JY. Enhancing life or eradicating ugliness? Lifestyle drugs. J Manage Care Pharm 2002; 8: 15-20.
30. Patel H. Lifestyle drugs. Caremark Clinical update 2000 (July).
31. Bogdanovic S, Langlands B. Lifestyle drugs patient-initiated prescribing. Consultant Report 2003. Southend-on-Sea: Nicholas Hall & Company.
32. Kole PL, Bhusari S, Thakurdesai PA. Lifestyle drugs: new avenues. Internet Communication 2003.
33. Atkinson T. Lifestyle drug market booming. Nat Med, 2002; 8: 909.
34. Gebhart F. Patient demand for lifestyle drugs putting R.Ph.s in a bind. Drug Topic 1999; 143:61.
35. Happier, hornier, hairier. Editorial. Nat Biotechnol 2003; 21: 1.